Orexigen hoping for quicker resubmission path for weight-loss drug
This article was originally published in Scrip
Executive Summary
Chomping at the bit to get into the horse race in the antiobesity market – with the US FDA already approving two new drugs in recent months to treat the condition, Vivus' Qsymia (phentermine and topiramate) and Arena Pharmaceuticals' and Eisai's Belviq (lorcaserin) – Orexigen Therapeutics gave investors new hope its experimental medicine Contrave (naltrexone/bupropion) may have a quicker path to the finish line than earlier thought.